Overview

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Status:
Withdrawn
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous T-cell lymphoma (CTCL).
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Treatments:
Antibodies, Monoclonal
Durvalumab